Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA firms up on how public hearings on marketed drugs will be run

This article was originally published in SRA

Executive Summary

The European Medicines Agency is inviting feedback on how its pharmacovigilance committee, the PRAC, should organize and conduct the public hearings that the committee is planning to hold as part of certain safety reviews of medicines1,2. The hearings would open the process of assessing medicines in the EU to the public for the first time3.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS117874

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel